2019年11月15日 · Valeritas’ flagship product, V-Go ® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for adult patients requiring insulin that is worn...

2020年2月10日 · Long-troubled Valeritas, manufacturers of a wearable, disposable insulin pump, has filed for Chapter 11 bankruptcy as part of a plan to hand off its business to the specialty drugmaker Zealand ...

2017年3月29日 · Valeritas Holdings, Inc.是一家商业化的医疗技术公司，专注于通过开发和商业化创新技术来改善健康和简化糖尿病患者的生活。Valeritas目前已经设计并上市了第一个产品：V-Go穿戴式胰岛素输送装置（V-Go），帮助需要胰岛素的2型糖尿病患者达到并维持其目标血糖目标。

2020年4月2日 · Zealand Pharma (NASDAQ: ZEAL) has acquired Valeritas Holdings, Inc. (NASDAQ: VLRX), a U.S. based commercial-stage company for a cash purchase price of $23 million

Valeritas是一家专注糖尿病治疗的医疗技术公司，致力于创新型药物供应解决方案的开发和商业化，为患者带去临床和人道解决方案。 研发解决方案 商业解决方案

2020年2月10日 · Valeritas' flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for adult patients requiring insulin that is worn...

The V-Go is a simple-to-use, once-daily, disposable insulin delivery device. This spring-driven patch pump is worn on the skin to provide a preset basal rate and on-demand bolus dosing. Valeritas designed the device to be convenient and easy to use for people with Type 2 diabetes who use multiple daily injections. One of the V-Go’s great ...

Valeritas | 3,769 followers on LinkedIn. Improving health and simplifying life for people with diabetes. | We are a commercial-stage medical technology company focused on improving health and ...

2022年5月18日 · 近日，以2300万美元购入Valeritas的西兰制药公司以1000万美元的价格将V-GO技术及项目组转让给了MannKind，价格腰斩。 要知道，西兰制药愿意花2300万美元的价格收购Valeritas就是因为其V-GO项目。

Valeritas 为成人二型糖尿病患者设计了一款按需注射胰岛素的产品——V-Go，这是一种小型的、一次性的胰岛素注射装置，需要 24 小时贴在皮肤上。